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The authors nicely demonstrate,1 in a mixed cohort of asymptomatic and 
symptomatic patients, that the prevalence of non-calcified plaque is not 
insignificant among those persons with calcium score of zero.   Understanding the 
differences between the symptomatic and asymptomatic cohorts are most 
important and that wasn’t well delineated in the manuscript.  Prevalence of disease,
significance of non-calcified plaque and pre-test probability are all important factors
that vary based on symptomatology.  Regardless, there were significant 
percentages of non-calcified plaque and high risk plaque (8.4%) among those with 
zero scores.  However, major adverse cardiovascular events (MACE) were 
exceptionally low, reaffirming the ‘power of zero’ of a calcium score.   It has been 
shown in numerous papers and numerous prospective studies that a zero score 
confers a very low risk of MACE, which was re-confirmed in this study. 2   The 
composite MACE rate for scores of zero was 0.54% over 6.6 years of follow up, 
resulting in a <0.1%/year event rate.    Despite the findings of non-calcified plaque 
and high risk plaque (both of which have mixed data regarding outcomes, especially
in asymptomatic persons), the hard endpoint of MACE was extremely low, calling 
into question the importance of non-calcified plaque and subsequent cardiovascular
events.   Pathologic studies suggest that a mixed plaque (one with both 
components of non-calcified and calcified plaque) are most worrisome,3 so it is 
possible that this isolated non-calcified plaque is not a major concern, reaffirming 
the need for calcium scores for risk stratification. 
The authors spend a fair amount of time suggesting that ultra-low calcium scores 
(those <1.0) have higher prevalence of disease than those with scores of zero, yet 
the MACE event rate for this group was identical to the zero score population (0.6 vs
0.54%, p=0.743).  It is unclear if these scores represent actual coronary 
calcification that were not previously identified, or if these represent areas of 
increase attenuation due to image noise.    Regardless, the low event rate of 
patients with these features is reassuring.   This suggest that one can safely 
consolidate those patients with ultra-low calcium scores with the zero score, as the 
primary goal of risk stratification is to identify those persons who are at risk of 
future ASCVD event, and start appropriate therapies to reduce those events.   This 
paper (with 6.6 year median follow up) strongly reinforces the new 2018 ACC/AHA 
Cholesterol guidelines4 and the 2019 ACC/AHA Prevention guidelines5 which suggest
that those persons with zero scores do not need statin therapy for 5-10 years.
Given the goal of the CAC score is to risk stratify individuals, and minimal and
zero calcified plaque have similar outcomes, there appears no added value 
to characterizing the minimal non-calcified plaque or high risk plaque in this 
low risk population.
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